Russia's personalised mRNA cancer vaccine shows success in first patient, researcher says

A Russian personalised mRNA cancer vaccine, Enteromix, has shown successful results after three years of research, according to Alexander Gintsburg, Director of Russia's National Medical Research Institute.
The vaccine is prepared to suit an individual's specific genetic profile. Gintsburg stated that the first volunteer patient has completed the full treatment course and is recovering well.
Four months after finishing treatment, continuous CT scans at the National Medical Research Centre for Radiology showed no signs of new cancer development. Gintsburg said the patient will remain under observation for the next three years.